Parnaparin in surgery, vascular surgery and associated disciplines

Aliterature review is dedicated to the use of Parnaparin in various surgical specialties. Prevention and treatment of thromboembolic complications is the major indication for the use of Parnaparin. In the review, the authors dwell on comparative studies of the efficacy oflow molecular weight heparins and unfractionated heparin. They also discuss in detail pharmacokinetics and pharmacodynamics of Parnaparin, its structure and effect on hemostasis components. Due tolack of direct comparative studies of variouslow molecular weight heparins, the authors provide reviews based on the network meta-analysis, which allowed them to identify the advantages of a specificlow molecular weight heparin by indirect comparison.
There are few direct comparative studies of variouslow molecular weight heparins in theliterature, which does not allow for an objective assessment of their advantages and disadvantages. The authors do not only provideliterature data on direct comparative studies, but also show data on indirect comparisons (network meta-analysis). They analysed the efficacy of Parnaparin and otherlow molecular weight heparins for the prevention of thromboembolic complications, treatment of deep vein thrombosis and post-thrombophlebitic syndrome. The issues of the efficacy of Parnaparin in chronic arterial insufficiency and use in acute coronary syndrome are highlighted separately. The final part of the review is concerned with a promising, butlittle-known area of prophylaxis of restenosis and prevention of atherosclerosis progression. Experimental studies have allowed us to state that Parnaparin is one of the most effectivelow molecular weight heparins as far as thromboembolic complications are concerned. Parnaparin significantly reduces frequency of DVT events and, at the same time, decreases major bleeding risk as compared with unfractionated heparin. No dose adjustment is required in obese patients. Dose adjustments are based not on body weight but on risk factors for thrombosis, and obesity is only one of them to be considered to choose a dose. Amonglow molecular weight heparins, Parnaparin is one of the most potent drugs that reduces the proliferative and migratory capacity of smooth muscle cells; however, further research is needed to assess the prospects of using Parnaparin for the prevention of restenosis.

1. Kopenkin S.S. Prevention of venous thromboembolic complications in traumatology and orthopedics. Khirurgiya. Consilium Medicum = Surgery. Consilium Medicum. 2005;(1):15-20. (In Russ.) Available at: https://elibrary.ru/item.asp?id=27002119&.

2. Kolbin A.S., Galankin T.K. Pharmacoeconomic analysis of parnaparin (Fluxum®) use for the prevention of venous thromboembolic events after surgery and for the treatment of thrombophlebitis of superficial veins. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2017;26(1):66-71. (In Russ.) Available at: https://clinpharm-journal.ru/files/articles/farmakoekonomicheskij-analiz-primeneniya-parnaparina-flyuksum-dlya-profilaktiki-venoznyh-tromboembolicheskih-oslozhnenij-pri-hirurgicheskih-vmeshatelstvah-i-dlya-lecheniya-tromboflebita-poverhnostnyh.pdf.

3. Silvain J., Beygui F., Barthelemy O., Pollack C.Jr., Cohen M., Zeymer U. et al. Efficacy and safety of enoxаparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553. doi: 10.1136/bmj.e553.

4. Murphy S.A., Gibson C.M., Morrow D.A., Van de Werf F., Menown I.B., Goodman S.G. et al. Efficacy and safety of thelow-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007;28(14):2077-2086. doi: 10.1093/eurheartj/ehm224.

5. Della Marchina M., Renzi G., Palazzini E. Treatment of phlebopathies withlow molecular weight heparin as compared to calcium heparin. Rif Med. 1988;104:99.

6. Dettori A.G., Tagliaferri A., Dall'Aglio E., Pini M. Clinical pharmacology of a newlow molecular weight heparin (Aifa-LMWH-Fluxum). Int Angiol. 1988;7(3S):7-18. Available at: https://pubmed.ncbi.nlm.nih.gov/2850327/

7. Morozov K.M., Kolbin A.S., Galankin T.L. Network meta-analysis for Parnaparine efficiency in venous thromboembolic prevention in surgery. Tromboz, gemostaz i reologiya = Thrombosis, Hemostasis and Rheology. 2018;(1):31-39. (In Russ.) Available at: https://thrj.ru/index.php/thrj/article/view/133.

8. Bokeriya L.A., Zatevakhin I.I., Kirienko A.I., Andriyashkin A.V., Andriyashkin V.V., Arutyunov G.P. et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). Flebologiya = Flebology. 2015;9(4-2):2-52. (In Russ.) Available at: https://elibrary.ru/contents.asp?id=34347895.

9. Tikhilov R.M. (ed.). Prevention of venous thromboembolic complications in traumatology and orthopedics. Russian clinical guidelines. Travmatologiya i ortope-diya Rossii = Traumatology and Orthopedics of Russia. 2012;1(appendix). (In Russ.) Available at: http://webmed.irkutsk.ru/doc/pdf/peortoped.pdf.

10. The national standard of the Russian Federation GOST R 56377-2015. Clinical guidelines (treatment protocols). Prevention of thromboembolic syndromes. Problemy standartizatsii v zdravookhranenii = Health Care Standardization Problems. 2015;(7-8):28-68. (In Russ.)

11. Rumyantsev A.G., Moroz V.V., Plavunov N.F. Pulmonary embolism: diagnosis, clinic, treatment. Moscow: Gemostaz i Reologiya; 2012. (In Russ.)

12. Poddubnaya I.V., Savchenko V.G. (eds.). Russian clinical guidelines for diagnosis and treatment of lymphoproliferative diseases. Moscow; 2016. 419 p. (In Russ.) Available at: http://www.hematology.ru/oncohematology/standarts/clinical_guidelines-draft.pdf.

13. McKeage K., Keating G.M. Parnaparin: a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs. 2008;68(1):105-122. doi: 10.2165/00003495200868010-00007.

14. Verhaeghe R. The use oflow-molecular-weight heparins in cardiovascular disease. Acta Cardiol. 1998;53(1):15-21. Available at: https://pubmed.ncbi.nlm.nih.gov/9638965/

15. Bonomini F., Taurone S., Parnigotto P., Zamai L., Rodella L.F., Artico М., Rezzani R. Role of parnaparin in atherosclerosis. Int J Exp Pathol. 2016;97(6):457-464. doi: 10.1111/iep.12217.

16. Camporese G., Bernardi E., Noventa F. Update on the clinical use of thelow-molecular-weight heparin, parnaparin. Vasc Health Risk Manag. 2009;5:819-831. doi: 10.2147/vhrm.s3430.

17. Frampton J.E., Faulds D. Parnaparin: a review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs. 1994;47(4):652-676. doi: 10.2165/00003495-199447040-00007.

18. Dettori A.G., Tagliaferri A., Dall'Aglio E., Pini M. Clinical pharmacology of a newlow molecular weight heparin (alfa LMWH-Fluxum). Int Angiol. 1988;7(3S):7-18. Available at: https://pubmed.ncbi.nlm.nih.gov/2850327.

19. Palareti G., Legnani C., Bianchini B., Guazzaloca G., Maccaferri M., Marabini A. et al. Pharmacodynamic effects on blood coagulation of a newlow molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecologic surgery patients. Int Angiol. 1989;8(1):47-52. Available at: https://pubmed.ncbi.nlm.nih.gov/2768958.

20. Kopenkin S.S. Prevention of venous thromboembolic complications in traumas oflocomotor system. Meditsinskiy sovet = Medical Council. 2016;(10):143-147. (In Russ.) doi: 10.21518/2079-701X-2016-10-143-147.

21. Palmieri G.C., Ambrosi G., Ferrero G., Palazzini E., Cossarizza A., Agrati A. Kinetic control in healthy volunteers oflow molecular weight heparin antithrombotic activity. Riv Eur Sci Med Farmacol. 1988;10(3):187-192. Available at: https://pubmed.ncbi.nlm.nih.gov/2856292.

22. Maugeri N., de Gaetano G., Barbanti M., Donati M.B., Cerletti C. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, alow molecular weight heparin. Haematologica. 2005;90(6):833-839. Available at: https://pubmed.ncbi.nlm.nih.gov/15951297.

23. Melandri G., Semprini F., Cervi V., Candiotti N., Branzi A., Palazzini E., Magnani B. Comparison of efficacy oflow molecular weight heparin (parnapa-rin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol. 1993;72(5):450-454. doi: 10.1016/0002-9149(93)91139-9.

24. Florian-Kujawski M., Hoppensteadt D., Maddineni J., Ziegler H., Fareed J. Differential regulation of thrombin activatable fibrinolytic inhibitor bylow molecular weight heparins. Pharmacologic implications. Int Angiol. 2004;23(4):346-354.

25. Prandoni P., Siragusa S., Girolami B., Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated withlow-molecular-weight heparin: a prospective cohort study. Blood. 2005;106(9):3049-3054. doi: 10.1182/blood-2005-03-0912.

26. Sartori M., Favaretto E., Migliaccio L., Guazzaloca G., Legnani C., Palareti G., Cosmi B. The incidence of heparin-induced thrombocytopenia in patients treated withlow molecular weight heparin for superficial vein thrombosis. Thromb Res. 2016;139:154-157. doi: 10.1016/j.thromres.2016.02.004.

27. Chiapuzzo E., Orengo G.B., Ottria G., Chiapuzzo A., Palazzini E., Fusillo M. The use oflow molecular weight heparins for postsurgical deep vein thrombosis prevention in orthopaedic patients. J Int Med Res. 1988;16(5):359-366. doi: 10.1177/030006058801600505.

28. Pini M., Tagliaferri A., Manotti C., Lasagni F., Rinaldi E., Dettori A.G. Low molecular weight heparin (alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. Int Angiol. 1989;8(3):134-139. Available at: https://pubmed.ncbi.nlm.nih.gov/2556484.

29. Verardi S., Casciani C.U., Nicora E., Forzano F., Origone A., Valle I. et al. A multicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis. Int Angiol. 1988;7(3S):19-24. Available at: https://pubmed.ncbi.nlm.nih.gov/2850322/

30. Mascali F., Condorelli A., Salanitiri G. Postsurgery thromboembolism prevention by LMW heparin subcutaneous administration. Eur Rev Med Pharmacol Sci. 1988;10:135-141.

31. Verardi F., Cortese F., Baroni B. Deep vein thrombosis prevention in surgical patients: effectiveness and safety of a new alow molecular weight heparin. Curr Ther Res. 1989;46:366-372.

32. Beghi C., Fragnito C., Antonelli A., Reverberi C., Ferrari P., Saccani S., Fesani F. Prevention of deep venous thrombosis by a newlow molecular weight heparin (Fluxum) in cardiac surgery. Int Angiol. 1993;12(4):383-386. Available at: https://pubmed.ncbi.nlm.nih.gov/8207317.

33. Speziale F., Verardi S., Taurino M., Nicolini G., Rizzo L., Fiorani P., Palazzini E. Low molecular weight heparin prevention of post-operative deep vein thrombosis in vascular surgery. Pharmatherapeutica. 1988;5(4):261-268. Available at: https://pubmed.ncbi.nlm.nih.gov/3174726/

34. Corrado F., Fini M., Severini G., Benati A., Monetti N. Low-molecular weight heparin (Fluxum) prevention of post-operative thrombosis in urological surgery: a controlled study. Clin Trials J. 1989;26:138-148.

35. Montebugnoli M., Bugamelli S., Calo P., Zangheri E., Ferrari P. Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin. Clin Appl Thromb Hemost. 2007;13(3):249-258. doi: 10.1177/1076029607302667.

36. Catania G., Salanitri G. Prevention of postoperative deep vein thrombosis by two different heparin types. Int J Clin Pharmacol Ther Toxicol. 1988;26(6):304-309. Available at: https://pubmed.ncbi.nlm.nih.gov/2842266.

37. Scholten D.J., Hoedema R.M., Scholten S.E. A comparison of two different prophylactic dose regimens oflow molecular weight heparin in bariatric surgery. Obes Surg. 2002;12(1):19-24. doi: 10.1381/09608920 2321144522.

38. Handeland G.F., Abildgaard U., Holm H.A., Arnesen K.E. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated andlow molecular weight heparin. Eur J Clin Pharmacol. 1990;39(2):107-112. doi: 10.1007/BF00280041.

39. Imberti D., Baldini Е., Pierfranceschi M.G., Nicolini А., Cartelli С., Boni M. et al. Prophylaxis of venous thromboembolism withlow molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obes Surg. 2014;24(2):284-291. doi: 10.1007/s11695-013-1105-x.

40. Wilson S.J., Wilbur K., Burton E., Anderson D.R. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage oflow-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31(1):42-48. doi: 10.1159/000048043.

41. Sjostrom L., Lindroos A.K., Peltonen M., Torgerson J., Bouchard C., Carlsson B. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683-2693. doi: 10.1056/NEJMoa035622.

42. Brasileiro A.L., Miranda Jr.F., Ettinger J.E., Castro A.A., Pitta G.B.B., de Moura L.K. et al. Incidence oflowerlimbs deep vein thrombosis after open andlaparoscopic gastric bypass: a prospective study. Obes Surg. 2008;18(1):52-57. doi: 10.1007/s11695-007-9268-y.

43. Du W., Zhao С., Wang J., Liu J., Shen В., Zheng Y. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism afterlumbar spine surgery. J Orthop Surg Res. 2015;10:78. doi: 10.1186/s13018-015-0223-7.

44. Prandoni P., Lensing A.W., BQller H.R., Carta M., Cogo A., Vigo M. et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992:339(8791):441-445. doi: 10.1016/0140-6736(92)91054-c.

45. Hull R.D., Raskob G.E., Pineo G.F., Green D., Trowbridge A.A., Elliott C.G. et al. Subcutaneouslow-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992:326(15):975-982. doi: 10.1056/NEJM199204093261502.

46. Koopman M.M.W., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P., van der Meer J. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneouslow-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334(11):682-687. doi: 10.1056/NEJM199603143341102.

47. Bellosta R., Ferrari Р., Luzzani L., Carugati С., Cossu L., Talarico M., Sarcina A. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations. Angiology. 2007;58(3):316-322. doi: 10.1177/0003319707301757.

48. Sannazzari P. Low molecular weight heparin in the symptomatic treatment of chronic venous insufficiency. Controlled double blind study vs calcium heparin. Panminerva Med. 1989;31(3):127-133. Available at: https://pubmed.ncbi.nlm.nih.gov/2557572/

49. Canova R., Celentano R., Gasbarrone L. Long-term treatment of patients with post-phlebitic syndrome by means of a newlmw-heparin. NAM. 1993;9:318-324.

50. PRIME CARE Study Investigators Group. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study. Indian Heart J. 2005;57(6):648-654. Available at: https://pubmed.ncbi.nlm.nih.gov/16521631/

51. Wang X.-K., Zhang Y., Yang C.-M., Liu G.-Y. Use of unfractionated heparin and alow-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction. Clin Drug Invest. 2006;26(6):341-349. doi: 10.2165/00044011200626060-00005.

52. Mannarino E., Pasqualini L., Innocente S., Orlandi U., Scricciolo V., Lombardini R., Ciuffetti G. Efficacy of low-molecular-weight heparin in the management of intermittent claudication. Angiology. 1991;42(1):1-7. doi: 10.1177/000331979104200101.

53. Calabro A., Piarulli F., Milan D., Rossi A., Coscetti G., Crepaldi G. Clinical assessment oflow molecular weight heparin effects in peripheral vascular disease. Angiology. 1993;44(3):188-195. doi: 10.1177/0003319 79304400304.

54. Simoni G., Lucertini G., Decian F. Low molecular weight heparins: therapeutic insight in peripheral arterial occlusive disease. Clin Trials Metaanal. 1993;28(3):137-145. Available at: https://moh-it.pure.elsevier.com/en/publications/low-molecular-weight-heparins-therapeutic-insight-in-periph-eral-a.

55. Tesi M., Bronchi G.M., Carini A. et al. Efficacy and safety of a newlow-molecular weight heparin in the medium-term treatment of atherosclerotic arteriopa-thy of the lower limbs. J Drug Dev. 1989;2:73-82.

56. Serrao E., Mangialardi N. Treatment of peripheral arteriopathies with a newlow weight heparin. Results of a double blind, controlled study. Panminerva Med. 1991;33(4):197-204. Available at: https://pubmed.ncbi.nlm.nih.gov/1806878.

57. Palmieri G., Ambrosi G., Agrati A.M., Ferraro G., Marcozzi S. A newlow molecular weight heparin in the treatment of peripheral arterial disease. Int Angiol. 1988;7(3S):41-47. Available at: https://pubmed.ncbi.nlm.nih.gov/2850326.

58. Cao Q., Jiang Y., Shi J., Xu C., Liu X., Yang T. et al. Artemisinin inhibits the proliferation, migration, and inflammatory reaction induced by tumor necrosis factor-а in vascular smooth muscle cells through nuclear factor kappa B pathway. J Surg Res. 2015:194(2):667-678. doi: 10.1016/j.jss.2014.12.013.

59. Schiffrin E.L., Lipman M.L., Mann J.F.E. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007:116(1):85-97. doi: 10.1161/CIRCULATIONAHA.106.678342.